The Centers for Medicare and Medicaid Services finalized a rule on September 15, 2025, expanding Medicare Part D coverage of GLP-1 receptor agonist drugs — including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — to treat obesity as a standalone condition, not just as a treatment for Type 2 diabetes. CMS estimated 3.5 million Medicare beneficiaries would be newly eligible. The rule's details are confirmed by CMS, Fox News, NPR, CNBC, and the American Diabetes Association.
Prior to the rule, Medicare was prohibited by a 2003 statute from covering drugs for weight loss. CMS's new interpretation held that GLP-1 drugs treat obesity as a disease — not merely for cosmetic weight loss — and therefore fell outside the statutory exclusion. The rule was challenged in court by conservative legal groups arguing that CMS had exceeded its statutory authority.
The estimated annual cost of the expansion was $7 billion to Medicare over 10 years, according to CBO. Drug manufacturers Novo Nordisk and Eli Lilly saw their stock prices rise on the announcement. The list price for Wegovy was approximately $1,350 per month without insurance; Medicare's negotiated rate would be significantly lower under the Inflation Reduction Act drug pricing provisions.
NPR and health advocates said the rule addressed a gap that left lower-income Medicare beneficiaries without access to drugs that could meaningfully reduce obesity-related heart disease, diabetes, and mortality. Fox News and fiscal conservative groups said $7 billion annually for 'lifestyle drugs' was difficult to justify when Medicare faced long-term solvency issues. Both sides acknowledged the clinical evidence for GLP-1 drugs' effectiveness in reducing cardiovascular events was strong.
Left-Leaning Emphasis
- NPR emphasized that lower-income Medicare beneficiaries had been unable to afford GLP-1 drugs at $1,350/month without coverage.
- Left outlets said the rule addressed a 'cruel gap' that left obese seniors without access to evidence-based treatment.
- NPR cited studies showing GLP-1 drugs reduce heart attacks and strokes in at-risk populations.
Right-Leaning Emphasis
- Fox News and fiscal conservative groups questioned whether Medicare should cover $7B/year in 'lifestyle medication.'
- Daily Wire noted that the drug's efficacy requires indefinite use — patients regain weight when they stop — raising long-term cost concerns.
- Right outlets cited Medicare's $36 trillion in long-term unfunded liabilities as context for any new coverage expansions.